These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38279317)

  • 1. The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.
    Chuang TD; Ton N; Rysling S; Boos D; Khorram O
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Expression of Super-Enhancer-Associated Long Non-coding RNAs in Uterine Leiomyomas.
    Chuang TD; Quintanilla D; Boos D; Khorram O
    Reprod Sci; 2022 Oct; 29(10):2960-2976. PubMed ID: 35641855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Expression of MED12-Associated Coding RNA Transcripts in Uterine Leiomyomas.
    Chuang TD; Gao J; Quintanilla D; McSwiggin H; Boos D; Yan W; Khorram O
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Profiling of lncRNAs, miRNAs, and mRNAs and Their Differential Expression in Leiomyoma Using Next-Generation RNA Sequencing.
    Chuang TD; Khorram O
    Reprod Sci; 2018 Feb; 25(2):246-255. PubMed ID: 28587571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
    Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
    Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
    Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
    Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
    Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
    Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
    Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial differences in transcriptomics and reactive oxygen species burden in myometrium and leiomyoma.
    Li Y; McNally RP; Feng Y; Kim JJ; Wei JJ
    Hum Reprod; 2023 Apr; 38(4):609-620. PubMed ID: 36749068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
    Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
    Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
    Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
    Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
    Croce S; Chibon F
    Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular matrix (ECM) activates β-catenin signaling in uterine fibroids.
    Ko YA; Jamaluddin MFB; Adebayo M; Bajwa P; Scott RJ; Dharmarajan AM; Nahar P; Tanwar PS
    Reproduction; 2018 Jan; 155(1):61-71. PubMed ID: 29066531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
    Di Tommaso S; Tinelli A; Malvasi A; Massari S
    Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
    Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
    Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Noncoding RNA MIAT Modulates the Extracellular Matrix Deposition in Leiomyomas by Sponging MiR-29 Family.
    Chuang TD; Quintanilla D; Boos D; Khorram O
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34491311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of
    Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
    Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities.
    Bateman NW; Abulez T; Tarney CM; Bariani MV; Driscoll JA; Soltis AR; Zhou M; Hood BL; Litzi T; Conrads KA; Jackson A; Oliver J; Ganakammal SR; Schneider F; Dalgard CL; Wilkerson MD; Smith B; Borda V; O'Connor T; Segars J; Shobeiri SA; Phippen NT; Darcy KM; Al-Hendy A; Conrads TP; Maxwell GL
    Am J Obstet Gynecol; 2024 Sep; 231(3):321.e1-321.e11. PubMed ID: 38723985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.